These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33973301)

  • 1. Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta-Analysis.
    Nielson CM; Bylsma LC; Fryzek JP; Saad HA; Crawford J
    Oncologist; 2021 Sep; 26(9):e1609-e1618. PubMed ID: 33973301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
    Kim G; Cockrum P; Surinach A; Wang S; Wainberg Z
    Curr Med Res Opin; 2022 Aug; 38(8):1295-1303. PubMed ID: 35354375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum-containing regimens for metastatic breast cancer.
    Egger SJ; Willson ML; Morgan J; Walker HS; Carrick S; Ghersi D; Wilcken N
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003374. PubMed ID: 28643430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
    Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
    BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
    Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
    Skoetz N; Will A; Monsef I; Brillant C; Engert A; von Tresckow B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD007941. PubMed ID: 28541603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z
    Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status.
    Gijtenbeek RG; de Jong K; Venmans BJ; van Vollenhoven FH; Ten Brinke A; Van der Wekken AJ; van Geffen WH
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD013382. PubMed ID: 37419867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in chemotherapy relative dose intensity decreases overall survival of neoadjuvant chemoradiotherapy in patients with locally advanced esophageal carcinoma.
    Jiang L; Zhu J; Chen X; Wang Y; Wu L; Wan G; Han Y; Leng X; Zhang J; Peng L; Wang Q
    BMC Cancer; 2024 Aug; 24(1):945. PubMed ID: 39095767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxanes for adjuvant treatment of early breast cancer.
    Willson ML; Burke L; Ferguson T; Ghersi D; Nowak AK; Wilcken N
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD004421. PubMed ID: 31476253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
    Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
    Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of the impact of dose delay and reduction on outcomes of colorectal cancer patients treated with FOLFIRI‑based treatment.
    Zhang X; Zheng H; Cai C; Xu Y; Xie M; Wang Q; Jin X; Fu J
    PeerJ; 2023; 11():e15995. PubMed ID: 37719110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum-containing regimens for triple-negative metastatic breast cancer.
    Egger SJ; Chan MMK; Luo Q; Wilcken N
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013750. PubMed ID: 33084020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
    Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
    JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.
    Chevalier H; Vienot A; Lièvre A; Edeline J; El Hajbi F; Peugniez C; Vernerey D; Meurisse A; Hammel P; Neuzillet C; Borg C; Turpin A
    Oncologist; 2020 Nov; 25(11):e1701-e1710. PubMed ID: 32886823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer.
    Hanna RK; Poniewierski MS; Laskey RA; Lopez MA; Shafer A; Van Le L; Crawford J; Dale DC; Gehrig PA; Secord AA; Havrilesky LJ; Lyman GH
    Gynecol Oncol; 2013 Apr; 129(1):74-80. PubMed ID: 23262376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
    Pointet AL; Tougeron D; Pernot S; Pozet A; Béchade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Williet N; Desrame J; Artru P; Soularue E; Le Roy B; Taieb J
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):295-301. PubMed ID: 31607641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2J2
    Ahmed JH; Makonnen E; Yimer G; Seifu D; Bekele A; Assefa M; Aseffa A; Howe R; Fotoohi A; Hassan M; Aklillu E
    Front Pharmacol; 2019; 10():481. PubMed ID: 31139078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.